Loading clinical trials...
Loading clinical trials...
A Prospective Study of Patients With B-Cell Hematologic Malignancies on Ibrutinib Therapy Who Are Infected With Coronavirus Disease 2019 (COVID-19)
Conditions
Interventions
Ibrutinib
Quality-of-Life Assessment
Locations
1
United States
Mayo Clinic in Rochester
Rochester, Minnesota, United States
Start Date
November 23, 2020
Primary Completion Date
November 19, 2021
Completion Date
July 22, 2022
Last Updated
August 3, 2022
NCT06846671
NCT07218341
NCT06548152
NCT07030400
NCT05006716
NCT07277231
Lead Sponsor
Academic and Community Cancer Research United
Collaborators
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions